Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Qilu Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07104110CT.gov Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT07406282CT.gov A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics | — | Recruiting | — | — | — |
NCT07086651CT.gov A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) | — | Completed | — | — | — |
NCT06430411CT.gov Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | — | Not Yet Recruiting | — | — | — |
NCT05849298CT.gov A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | — | Active Not Recruiting | — | — | — |
NCT06136650CT.gov A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | — | Recruiting | — | — | — |
NCT05191017CT.gov Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | — | Withdrawn | — | — | — |
NCT05252390CT.gov NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05022849CT.gov A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants | — | Completed | — | — | — |
NCT04033328CT.gov Study of ORIC-101 in Combination With Enzalutamide | — | Terminated | — | — | — |
Show 13 more trialsShow fewer
NCT03834493CT.gov Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) | — | Active Not Recruiting | — | — | — |
NCT04034095CT.gov A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan | — | Completed | — | — | — |
NCT03939689CT.gov I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). | — | Completed | — | — | — |
NCT03834519CT.gov Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) | — | Completed | — | — | — |
NCT03531827CT.gov Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | — | Terminated | — | — | — |
NCT03685591CT.gov PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02508636CT.gov Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer | — | Terminated | — | — | — |
NCT02453009CT.gov Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02034552CT.gov A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) | — | Completed | — | — | — |
NCT02446444CT.gov Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02446405CT.gov Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT01288911CT.gov A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT01284920CT.gov A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enzalutamide (this asset) | Qilu Pharmaceutical Co., Ltd. | P3 | B · 63 |
| Docetaxel | Merck Sharp & Dohme LLC | P4 | BBB |
| Degarelix | Novartis Pharmaceuticals | P4 | BBB |
| Prednisone | Merck Sharp & Dohme LLC | P3 | BBB |
| Leuporelin | Dana-Farber Cancer Institute | P4 | BB |
| Abiraterone | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Radium Ra-223 | Bayer | P3 | BB |
| Prednisolone | Eli Lilly and Company | P3 | BB |
| Gozetotide | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
+42 more in the Prostate Neoplasm cohort
Other indications for Enzalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P4 | BBB · 73 |
| Prostate Carcinoma | — | P4 | BBB · 73 |
| Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enzalutamide in Prostate Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enzalutamide-prostate-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →